A variant of the coronavirus found in the Republic of South Africa (South Africa) may, to some extent, “breakthrough” through the COVID-19 vaccine co-produced by the American Pfizer and the German BioNTech.
During the study, two expert groups analyzed 150 vaccinated Israeli citizens who tested positive for coronavirus.
The prevalence of the South African variant of the coronavirus among those vaccinated was eight times higher than among the unvaccinated population.
The authors note that the purpose of the work was not to study the effectiveness of the vaccine.
We found a disproportionately high rate of the South African variant among people vaccinated with the second dose compared to the unvaccinated group. This means that the South African variant can break through the protection of the vaccine to some extent.
Experts warned that the study has not yet passed peer review. Also, they note, the sample of people infected with the South African variant was small due to its rarity in Israel.